^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Anaplastic Astrocytoma

    Related cancers:
    5d
    NCI-2018-00876: Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> Sep 2026 | Trial primary completion date: May 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH1 mutation • IDH2 mutation
    |
    temozolomide • telaglenastat (CB-839)
    6d
    Prognostic Importance of Histomolecular Subtyping of Central Nervous System Gliomas in Low and Middle-Income Countries. (PubMed, Brain Tumor Res Treat)
    We provide empirical evidence supporting a role for histo-morphological and limited molecular testing in neuro-oncology practice in LMICs.
    Journal
    |
    TP53 (Tumor protein P53) • MGMT (6-O-methylguanine-DNA methyltransferase) • ATRX (ATRX Chromatin Remodeler)
    |
    TP53 mutation • MGMT promoter methylation • IDH wild-type
    6d
    Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma (clinicaltrials.gov)
    P1/2, N=40, Recruiting, National Institute of Neurological Disorders and Stroke (NINDS) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    IDH wild-type
    |
    LMP744
    7d
    Hemizygous deletion of CDKN2A/B in IDH-mutated glioma: Prognostic impact when adjusting for clinical factors. (PubMed, Neurooncol Adv)
    The presence of a hemizygous CDKN2A/B deletion occurs more frequently in astrocytomas compared to oligodendrogliomas at the time of primary diagnosis. Worse survival in patients with astrocytoma and CDKN2A/B hemizygous loss was observed, specifically in WHO grade 2, but this prognostic effect disappeared when adjusting for clinical factors.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
    |
    CDKN2A deletion
    10d
    Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas (clinicaltrials.gov)
    P1, N=30, Recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Dec 2026 --> May 2027 | Trial primary completion date: Dec 2026 --> May 2027
    Trial completion date • Trial primary completion date
    10d
    Optic glioma in children: clinical presentation, diagnosis, and management. (PubMed, Expert Rev Anticancer Ther)
    Because BRAF alterations are observed in most pilocytic astrocytomas, treatments targeting the MAPK pathway play an important role in the management of optic gliomas. Inhibition of the MAPK signaling pathway represents a potential advance in the treatment of optic gliomas.
    Review • Journal
    |
    BRAF (B-raf proto-oncogene) • NF1 (Neurofibromin 1)
    11d
    Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas (clinicaltrials.gov)
    P1, N=83, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Apr 2027
    Trial completion date
    |
    temozolomide • Zolinza (vorinostat)
    15d
    Association of Autophagy-Related Gene Expression Profiles with Survival in Diffuse Astrocytic Tumors. (PubMed, Cancers (Basel))
    This study demonstrates that increased expression of autophagy-related genes, particularly SQSTM1 and Beclin1, serves as a robust indicator of poor prognosis and shorter survival times in diffuse astrocytic tumors. Furthermore, the elevated expression of Beclin1 and Atg5 in IDH-mutant cases highlights a complex metabolic interplay that warrants further investigation as potential therapeutic targets.
    Journal • Gene Expression Profile
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • SQSTM1 (Sequestosome 1) • ATG5 (Autophagy Related 5) • ATG7 (Autophagy Related 7) • BECN1 (Beclin 1)
    |
    IDH wild-type • IDH1 R132
    17d
    First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma (clinicaltrials.gov)
    P1, N=9, Recruiting, Masonic Cancer Center, University of Minnesota
    New P1 trial • IO biomarker
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    MGMT promoter methylation
    |
    FT536
    21d
    Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma (clinicaltrials.gov)
    P=N/A, N=20, Active, not recruiting, Columbia University | Recruiting --> Active, not recruiting
    Enrollment closed
    25d
    Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors (clinicaltrials.gov)
    P=N/A, N=57, Terminated, Pediatric Brain Tumor Consortium | N=300 --> 57 | Trial completion date: Jul 2028 --> Apr 2026 | Suspended --> Terminated | Trial primary completion date: Jul 2027 --> Apr 2026; The NCI will not extend the PBTC grant beyond March 31, 2026.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Liquid biopsy • Circulating tumor DNA
    |
    IDH wild-type
    1m
    A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma (clinicaltrials.gov)
    P1, N=24, Recruiting, University of Nebraska | Trial completion date: Mar 2027 --> Jul 2029 | Trial primary completion date: Mar 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    temozolomide • abexinostat (CG-781)